Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Gunther Birznieks Sells 42,431 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Gunther Birznieks sold 42,431 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,904.37. Following the transaction, the senior vice president directly owned 494,197 shares in the company, valued at approximately $4,087,009.19. This trade represents a 7.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA traded down $0.10 on Thursday, hitting $8.10. The company’s stock had a trading volume of 195,341 shares, compared to its average volume of 2,844,654. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a one year low of $3.81 and a one year high of $9.60. The stock has a fifty day moving average of $7.56 and a two-hundred day moving average of $5.97. The firm has a market capitalization of $478.79 million, a P/E ratio of -2.17 and a beta of 0.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VNDA has been the subject of a number of research reports. Truist Financial started coverage on shares of Vanda Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $18.00 target price for the company. HC Wainwright raised their price objective on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. B. Riley Financial boosted their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.90.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Vanda Pharmaceuticals by 34.3% in the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 14,232 shares in the last quarter. Millennium Management LLC grew its position in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after buying an additional 1,470,898 shares in the last quarter. CWM LLC increased its stake in Vanda Pharmaceuticals by 424.6% during the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 7,575 shares during the period. Los Angeles Capital Management LLC raised its holdings in Vanda Pharmaceuticals by 17.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 44,696 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 6,765 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 4.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock valued at $7,986,000 after acquiring an additional 77,997 shares during the period. 88.14% of the stock is owned by institutional investors.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA granted a formal evidentiary public hearing to review CDER’s proposed refusal to approve Vanda’s sNDA for HETLIOZ in jet‑lag disorder — a rare, high‑visibility procedural win that gives Vanda a public forum to challenge the refusal and could materially improve approval odds if the hearing goes well. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ
• Positive Sentiment: Truist initiated coverage with a “Buy” rating and an $18 price target (~119% upside vs. current levels) — a new bullish analyst voice that can attract buyers and volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published 2027 quarterly EPS forecasts (and a $24 price target) — another sizable upside target that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Neutral Sentiment: Analyst coverage is mixed: while several firms maintain Buy/Overweight calls and high targets, there are recent downgrades and a consensus “Moderate Buy” with an average target near $14.90 — constructive overall but not unanimous. MarketBeat analyst summary
• Negative Sentiment: Multiple senior insiders sold sizable blocks of shares on/around March 2 (CEO, CFO, CMO, and SVPs combined disclosed sales totaling roughly $2.6M+) — coordinated insider selling often creates short‑term supply and can be perceived negatively by the market. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings formally disclose the individual insider trades (CEO filing and others), making the sales official and giving investors precise sizes/prices to evaluate motives (tax, diversification, or signal). SEC filing — CEO ownership disclosure

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.